



In the Claims:

1. (Previously Presented) A compound of the general formula I




where



R^p and R^q are each independently selected from hydrogen, halogen, optionally substituted C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₄-alkyloxy and optionally substituted phenyl;

W is O, S or an N-R^z group where R^z is selected from optionally substituted C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₄-alkyloxy and optionally substituted phenyl

and * denotes the bonding sites;



----- represents a single bond or a double bond;

R^v, R^w are each independently hydrogen, halogen, optionally substituted C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyloxy,


C₃-C₆-cycloalkyl-C₁-C₄-alkyloxy or C₃-C₆-cycloalkyl;

R^x, R^y are each independently hydrogen, halogen, optionally substituted C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₄-alkyloxy or C₃-C₆-cycloalkyl, or

R^x, R^y, together with the carbon atoms to which they are bonded, may also form a fused phenyl ring or a fused 5- or 6-membered aromatic heterocycle which has 1, 2, 3 or 4 heteroatoms which are selected from N, O and S, where the fused phenyl ring and the fused aromatic heterocycle may have 1, 2 or 3 substituents which are selected from optionally substituted C₁-C₆-alkyl, CN, OR¹, NR²R³, NO₂, SR⁴, SO₂R⁴, SO₂NR²R³, CONR²R³, COOR⁵, COR⁶, C₁-C₄-haloalkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₆-alkenyloxy, C₂-C₆-alkynyloxy, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkyloxy and halogen; where

R¹, R², R³, R⁴, R⁵ and R⁶ are each independently H, optionally substituted C₁-C₆-alkyl or optionally substituted phenyl, where R³ may also be a COR⁷ group where R⁷ is hydrogen, optionally substituted C₁-C₄-alkyl or optionally substituted phenyl, where R² with R³ may also together form a 5- or 6-membered, saturated or unsaturated carbocycle which may have a heteroatom selected from O, S and NR⁸ as a ring member, where R⁸ is hydrogen or C₁-C₄-alkyl,

D is a linear or branched 2- to 10-membered alkylene chain which may have, as chain members, a heteroatom group K which is selected from O, S, S(O), S(O)₂, N-R⁸, CO-O, C(O)NR⁸, and/or 1 or 2 nonadjacent carbonyl groups and which may include a cycloalkanediyl group and/or may have a double or triple bond;




is a saturated or monounsaturated, monocyclic nitrogen heterocycle having from 5 to 8 ring members or a bicyclic saturated nitrogen heterocycle having from 7 to 12 ring members, where the mono- and the bicyclic nitrogen heterocycle optionally has, as a ring member, a further heteroatom selected from oxygen, sulfur or nitrogen, where the mono- or bicyclic nitrogen heterocycle may be unsubstituted or bears an R^a radical, where

R^a is C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₁-C₁₀-alkoxycarbonyl, C₁-C₁₀-alkylcarbonyl, C₁-C₁₀-alkylsulfonyl, C₁-C₁₀-cyanoalkyl, C₃-C₁₀-


cycloalkyl, C₃-C₁₀-cycloalkyl-C₁-C₄-alkyl, C₃-C₁₀-cycloalkylcarbonyl, C₃-C₁₀-cycloalkylcarbonyl-C₁-C₄-alkyl, phenylcarbonyl, phenylcarbonyl-C₁-C₄-alkyl, phenoxycarbonyl, phenyl-C₁-C₁₀-alkyloxycarbonyl, 3- to 8-membered heterocyclylcarbonyl or 3- to 8-membered heterocyclylcarbonyl-C₁-C₄-alkyl, where heterocyclyl in the aforementioned radicals may have one, two or three heteroatoms selected from S, O and N, and

where the last 6 radicals may have, on the heterocycle or on the phenyl ring, 1, 2 or 3 substituents R^b which are each independently selected from optionally substituted C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₄-C₁₀-bicycloalkyl and C₆-C₁₀-tricycloalkyl, where the last three groups may optionally be substituted by halogen or C₁-C₄-alkyl, halogen, CN, OR¹, NR²R³, NO₂, SR⁴, SO₂R⁵, CONR²R³, SO₂NR²R³, COOR⁵, COR⁶, O-COR⁶, 5- or 6-membered heterocyclyl having 1, 2 or 3 heteroatoms selected from O, S and N, and phenyl, where phenyl and heterocyclyl in the last two substituents R^b may optionally bear one or two substituents which are each independently selected from C₁-C₄-alkyl, C₁-C₄-alkoxy, NR²R³, CN, C₁-C₂-fluoroalkyl and halogen, and where 2 substituents R^b bonded to adjacent carbon atoms of the aromatic radical may together be C₃- or C₄-alkylene, or, together with the carbon atoms to which they are bonded, may be a fused-on, unsaturated 5- or 6-membered carbocycle or a 5- or 6-membered heterocycle having 1 or 2 nitrogen atoms as ring members; or


R^a is an E-Ar group wherein E is a bond or linear or branched alkylene having from 1 to 4 carbon atoms and in particular (CH₂)_p, where p is 0, 1, 2, 3 or 4, and Ar is selected from phenyl, naphthyl and 5- or 6-membered heteroaryl which has one, two or three heteroatoms selected from S, O and N as ring members and which may optionally have 1, 2 or 3 of the aforementioned substituents R^b; or




is a saturated monocyclic nitrogen heterocycle having from 5 to 7 ring atoms which bears a fused-on benzene ring of the formula



where * denotes the bonding sites to the saturated monocyclic heterocycle; R^c may be the same or different and is as defined for R^b , and n is 0, 1, 2 or 3;

where  may optionally also have 1, 2, 3 or 4 further C₁-C₄-alkyl groups as substituents;


the physiologically acceptable acid addition salts of this compound and the tautomer of the formula I'



where R is halogen, an O-R¹ group where R¹ is as defined above, or an O-C(O)R⁹ group where R⁹ is hydrogen, optionally substituted C₁-C₆-alkyl, benzyl or phenyl, where the last two radicals are optionally substituted by one or two radicals which are each independently selected from C₁-C₄-alkyl, OH, C₁-C₄-alkoxy, NR²R³, CN, C₁-C₂-fluoroalkyl or halogen, and the physiologically acceptable acid addition salts of the tautomer I'.

2. (Previously Presented) A compound of the general formula I or I' as claimed in claim 1, where R^x, R^y, together with the carbon atoms to which they are bonded, are a fused phenyl ring or a fused 5- or 6-membered aromatic heterocycle which has 1, 2, 3 or 4 heteroatoms which are selected from N, O and S, where the fused phenyl ring and the fused aromatic heterocycle may have 1, 2 or 3 substituents which are selected from C₁-C₄-alkyl, C₁-C₄-hydroxyalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, CN, OR¹, NR²R³, NO₂, SR⁴, SO₂R⁴, SO₂NR²R³, CONR²R³, COOR⁵, COR⁶, C₁-C₂-fluoroalkyl, C₁-C₂-fluoroalkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₆-alkenyloxy, C₂-C₆-alkynyloxy, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkyl and halogen; where R¹, R², R³, R⁴, R⁵ and R⁶ are each independently as defined above.
3. (Currently Amended) A compound as claimed in ~~either of the preceding claims~~ claim 1, where D in the formulae I and I' is a (CH₂)_k group or a C(O)(CH₂)_l group, where k is 3, 4, 5 or 6 and l is 2, 3, 4 or 5.
4. (Currently Amended) A compound as claimed in ~~any of the preceding claims~~ claim 1, where A is N-C(O) in which the carbon atom is bonded to the variable B.

5. (Previously Presented) A compound as claimed in claim 4, where B is CH₂.
6. (Currently Amended) A compound of the general formula I or I' as claimed in ~~any of the preceding claims~~ claim 1, where



J is CH₂, CH₂-CH₂ or CH₂-CH₂-CH₂;


X is CH or N and

Y is CH₂, CH₂-CH₂ or CH₂-CH₂-CH₂, or Y-X together is CH=C or CH₂-CH=C;

R^e is hydrogen or C₁-C₄-alkyl.

7. (Previously Presented) A compound as claimed in claim 6, where J is CH₂-CH₂ and Y is CH₂.
8. (Currently Amended) A compound as claimed in claim 6 [[or 7]], where X is N.
9. (Previously Presented) A compound of the general formula I or I' as claimed in claim 6, where R^a is an E-Ar group where E and Ar are each as defined above.
10. (Previously Presented) A compound as claimed in claim 9, where E is a bond.
11. (Previously Presented) A compound as claimed in claim 10, where Ar is phenyl, pyridyl, pyrimidinyl or s-triazinyl, each of which has 1, 2 or 3 of the aforementioned R^b radicals.
12. (Previously Presented) A compound as claimed in claim 9, where E is CH₂.
13. (Previously Presented) A compound as claimed in claim 12, where Ar is phenyl, naphthyl, pyridyl, pyridinyl, pyrazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1-oxa-3,4-diazolyl or 1-thia-3,4-diazolyl, each of which is unsubstituted or may have 1, 2 or 3 of the abovementioned R^b radicals.

14. (Currently Amended) A compound as claimed in ~~any of claims~~ claim 6 [[to 8]], where R^a is C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkyl- C_1 - C_4 -alkyl, C_3 - C_{10} -cycloalkylcarbonyl- C_1 - C_4 -alkyl, C_3 - C_{10} -heterocycloalkyl- C_1 - C_4 -alkyl or C_3 - C_{10} -heterocycloalkylcarbonyl- C_1 - C_4 -alkyl.
15. (Previously Presented) A compound of the general formula I-Aa



where R^a , A, B and D are each as defined in claim 1;

m is 0, 1, 2 or 3;


R^d are each independently C_1 - C_4 -alkyl, C_1 - C_4 -hydroxyalkyl, C_1 - C_4 -alkoxy- C_1 - C_4 -alkyl, CN, OR^1 , NR^2R^3 , NO_2 , SR^4 , SO_2R^4 , $SO_2NR^2R^3$, $CONR^2R^3$, $COOR^5$, COR^6 , C_1 - C_2 -fluoroalkyl, C_1 - C_2 -fluoroalkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_2 - C_6 -alkenyloxy, C_2 - C_6 -alkynyloxy, C_3 - C_6 -cycloalkyl, C_3 - C_6 -cycloalkyl or halogen, where R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are each as defined in claim 1;

J is CH_2 , CH_2 - CH_2 or CH_2 - CH_2 - CH_2 ;

X is CH or N and


Y is CH_2 , CH_2 - CH_2 or CH_2 - CH_2 - CH_2 , or Y-X together is $CH=C$ or CH_2 - $CH=C$;

the physiologically acceptable acid addition salts of this compound and the tautomer of the formula I-A'a



where R is as defined in claim 1 and the physiologically acceptable acid addition salts of the tautomer Ia'.

16. (Previously Presented) A compound of the formula I-Ba



where R^a and D are each as defined in claim 1;

R^{x1}, R^{y1} are each independently hydrogen, halogen, optionally substituted C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₄-alkyloxy or C₃-C₆-cycloalkyl;

J is CH₂, CH₂-CH₂ or CH₂-CH₂-CH₂;

X is CH or N and

Y is CH₂, CH₂-CH₂ or CH₂-CH₂-CH₂, or Y-X together is CH=C or CH₂-CH=C;

and the physiologically acceptable acid addition salts of the compound I-Ba.

17. (Currently Amended) A compound as claimed in claim 15 [[or 16]], where J is CH₂-CH₂ and Y is CH₂.
18. (Currently Amended) A compound as claimed in ~~any of claims~~ claim 15 [[to 17]], where X is N.
19. (Currently Amended) A compound of the general formula I or I' as claimed in ~~any of claims~~ claim 15 [[to 18]], where R^a is an E-Ar group in which E and Ar are each as defined above.
20. (Previously Presented) A compound as claimed in claim 19, where E is a bond.
21. (Previously Presented) A compound as claimed in claim 20, where Ar is phenyl, pyridyl, pyrimidinyl or s-triazinyl, each of which has 1, 2 or 3 of the aforementioned R^b radicals.

22. (Previously Presented) A compound as claimed in claim 19, where E is CH₂.
23. (Previously Presented) A compound as claimed in claim 22, where Ar is phenyl, naphthyl, pyridyl, pyridinyl, pyrazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1-oxa-3,4-diazolyl or 1-thia-3,4-diazolyl, each of which is unsubstituted or may have 1, 2 or 3 of the abovementioned R^b radicals
24. (Currently Amended) A compound as claimed in ~~any of claims~~ claim 15 [[to 18]], where R^a is C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl-C₁-C₄-alkyl, C₃-C₁₀-cycloalkylcarbonyl-C₁-C₄-alkyl, C₃-C₁₀-heterocycloalkyl-C₁-C₄-alkyl or C₃-C₁₀-heterocycloalkylcarbonyl-C₁-C₄-alkyl.
25. (Currently Amended) A pharmaceutical composition comprising at least one active ingredient which is selected from compounds of the formula I, the tautomers of the formula I', the physiologically tolerated acid addition salts of the compounds I and the physiologically tolerated acid addition salts of the tautomers of the formula I' as claimed in ~~any of claims~~ claim 1 [[to 24]], optionally together with physiologically acceptable carriers and/or excipients.
26. (Currently Amended) The use of active ingredients which are selected from compounds of the formula I, the tautomers of the formula I', the physiologically tolerated acid addition salts of the compounds I and the physiologically tolerated acid addition salts of the tautomers of the formula I' as claimed in ~~any of claims~~ claim 1 [[to 24]] for producing a pharmaceutical composition for treating diseases which respond to the influence of dopamine D₃ receptor antagonists or agonists.
27. (Previously Presented) The use as claimed in claim 26 for treating diseases of the central nervous system.
28. (Previously Presented) The use as claimed in claim 26 for treating kidney function disorders.